Home J Young Pharm. Vol 17/Issue 2/2025 Effect of Sertraline in Newly Diagnosed Depression Patients with Post MI and Stroke: A Prospective Cohort Study

Effect of Sertraline in Newly Diagnosed Depression Patients with Post MI and Stroke: A Prospective Cohort Study

by [email protected]

1Department of Pharmacy Practice, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, Chennai, INDIA

2Compulsory Rotating Medical Internship, Shri Sathya Sai Medical College and Research Institute, Nellikuppam, INDIA

3Department of Psychiatry, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, INDIA

Corresponding author.

Correspondence: Dr. Karthik Sankar Department of Pharmacy Practice, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, Tamil Nadu, INDIA. Email: [email protected]
Received November 28, 2024; Revised January 11, 2025; Accepted April 02, 2025.
Copyright ©2025 Phcog.Net
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Citation

Published in: Journal of Young Pharmacists, 2025; 17(2): 477-482. Published online: 10 May 2025DOI: 10.5530/jyp.20251651

ABSTRACT

Background

Depression is a condition that affects mental health defined by persistent feelings of sadness and reduced interest in daily activities. Myocardial Infarction (MI) and stroke significantly contribute to global mortality and disability rates. Compared to other antidepressant medications, sertraline demonstrates a lower risk of overdose-related mortality, a reduced potential for dependence, and typically better tolerated by patients. The study focused on evaluating the efficacy of sertraline in managing newly diagnosed depression among patients who have suffered a stroke or MI.

Materials and Methods

A prospective cohort study includes participants assigned to two groups: Group A (post-MI depression) and Group B (post-stroke depression). We evaluated the severity of depression using HAM-D scores from baseline to Week 24, along with clinical parameters such as lipid profiles, HbA1c, blood pressure, and coagulation factors. We also measured medication adherence using MARS and assessed Health-Related Quality of Life (HRQoL) using RAND-36.

Results

This research comprised 129 participants, with 62 assigned to group A and 67 to group B. Statistical analysis indicated that sertraline resulted in symptom reduction of depression across both groups, with group B (Post-stroke patients) demonstrating a clinical enhancement in the HAM-D score at week 24. Post-stroke patients showed a more favorable response in TC, HDL, LDL, and TG levels compared to MI patients; Nevertheless, this variation did not achieve significance (p >0.05).

Conclusion

Sertraline effectively reduced depressive symptoms in both groups, with post-stroke patients demonstrating overall improvements in HAM-D scores, lipid profile, medication adherence, and HRQoL.

Keywords: Depression, Stroke, MI, Quality of life, Sertraline

 

INTRODUCTION

Depression is a psychological disorder defined by enduring feelings of sadness and a diminished ability to feel pleasure (Liet al., 2023). Myocardial Infarction (MI) and stroke are major contributors to global mortality and disability, largely due to their shared underlying mechanisms (Gandhi & Kishore, 2020). The pooled data shows that 23% of stroke patients experience depression, while the prevalence is slightly higher at 25.9% for those who have suffered a MI (Aw et al., 2022).

Antidepressants have proven to alleviate depression; their application in individuals with Cardiovascular Disease (CVD) remains a contentious issue. Sertraline is a well-known antidepressant from the SSRI class. It works by increasing serotonin levels in the brain by inhibiting its reabsorption (Padmapriyaet al., 2020) Sertraline is particularly notable for its lowers risk of overdose mortality and does not carry the potential for dependency (McRae & Brady, 2001). SSRIs has the ability to stabilize endothelial cells, suppress platelet activity. Nonetheless, the comprehensive clinical significance of these effects remains to be established (O’Connoret al., 2010; Stuckartet al., 2021). Evidence suggests that these agents may facilitate functional recovery following a stroke by modulating ischemia-induced hyper excitation, inflammation, and support the growth of new neurons in the hippocampus. SSRIs were discovered to lower depression levels without having any adverse cardiovascular effects in multiple studies (Gurbelet al., 2002). Despite numerous studies highlighting the advantages of sertraline for managing depression in patients with cardiovascular disease and stroke, there are still significant research gaps concerning its safety profile, long-term effects, and potential influence on cardiovascular outcomes (Liet al., 2017; Rasmussenet al., 2003). The aim of the present study was to evaluate the effects of sertraline in treating depression among patients who have experienced a stroke or MI.

MATERIALS AND METHODS

Study design and site

A cohort study was carried out over six months at the outpatient department of Psychiatry in a tertiary care teaching hospital.

Ethical consideration

The SRIHER (DU) Human Institutional Ethics Committee in Chennai, Tamil Nadu, India, approved the research protocol (CSP/19/NOV/81/409). The study followed the updated National Ethical Guidelines for Biomedical and Health Research Involving Human Participants from the Indian Council of Medical Research and all participants gave written informed consent.

Study criteria

Study participants aged 18 to 60 years, regardless of gender, who had experienced a MI or stroke and presented with manifestations of moderate depression during follow-up visits to the psychiatry outpatient department were involved in the study. These individuals were clinically assessed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition and with Hamilton Depression Rating Scale (HAM-D), taking into account on comorbidities related to stroke or MI. Patients with pre-existing mental disorders, patients on beta blockers or oral anticoagulants such as warfarin, anti-depressants including sertraline and refusing to provide written informed consent were excluded.

Study procedure

After obtaining consent form, demographic information and clinical data were gathered using a data collection performa. Lipid profiles, Apolipoprotein A and B (Apo A), (Apo B), Coagulation parameters, including Prothrombin Time (PT), and International Normalized Ratio (INR), Partial Thromboplastin Time (PTT) levels were recorded both at baseline and after 24 weeks of sertraline therapy. The study participants were categorized as 2 groups: Patients diagnosed with depression who had experienced a MI were in group A, while Group B included patients diagnosed with depression following a stroke. For those newly diagnosed with depression, sertraline tablets were prescribed at a dosage of 50 mg, to be taken twice daily alongside their standard medications. The treatment response was evaluated using the HAM-D scale. This was assessed both before and after the initiation of sertraline therapy over a period of 24 weeks. Additionally, medication adherence and Quality of Life (QoL) were measured at baseline and at week 24 by employing the Medication Adherence Rating Scale (MARS) and RAND-36 questionnaires.

Statistical analysis

Data analysis was conducted on Windows, utilizing SPSS version 29.0. Descriptive statistics were used to characterize the data, with n (%) used for categorical variables and the mean (SD) and median (IQR) for continuous variables. To check the normality of the data, the Shapiro-Wilk test was conducted. For between-group comparisons, the Mann-Whitney U test was employed, and Friedman’s test was applied, with subsequent pairwise comparisons using the Wilcoxon Signed Ranks test and Bonferroni correction was used for within-group comparisons. The Chi-square test was applied to assess the significance of categorical data. All statistical tests were two-tailed, with a p<0.05 was considered the threshold for significance in all the aforementioned statistical tools and all of the statistical tests performed were two-sided.

RESULTS

The study screened 148 patients totally and separated the participants into two distinct groups: group A included patients with depression due to MI, and group B included patients with depression following a stroke. Both groups received a prescription for a tablet containing 50 mg sertraline. There were a total of 19 dropouts, with 12 in group A and 7 in group B. Finally, 129 out of 148 patients met the eligibility criteria for inclusion, with 62 individuals assigned to group A and 67 to group B. Their demographic details are presented in Table 1. The occurrence of depression among MI and stroke patients was observed more frequently in males than in females. The median age for participants in group A was 52.24±2.7 years, whereas in group B, it was 53.4±3.2 years, showing no significance between the groups (p=0.474).

Characteristics Group A N=62 (%) Group B N=67(%) p-value
Age 52.24±2.7 53.4±3.2 0.474#
Gender
Male 35 (56.4) 42 (62.6) 0.470#
Female 27 (43.5) 25 (37.3)
Occupation
Employed 23 (37) 24 (35.8) 0.977#
Unemployed 34 (54.8) 37 (55.2)
Business 05 (8) 06 (10.4)
Education
Middle/high school 36 (58) 43 (64.1) 0.579#
Undergraduate 21 (33.8) 17 (25.3)
Postgraduate 05 (8) 07 (10.4)
Disease duration (years) 2.5±1.6 2.2±1.8 0.101#
Marital status
Single 15 (24.1) 21 (31.3) 0.368#
Married 31 (50) 24 (35.8)
Separated 09 (14.5) 08 (11.9)
Divorced 03 (4.8) 08 (11.9)
Widowed 04 (6.4) 06 (8.9)
Family type
Nuclear 30 (48.3) 33 (49.2) 0.435#
Joint 21 (33.8) 24 (35.8)
Extended 07 (11.2) 09 (13.4)
Living alone 04 (6.4) 01 (1.4)
Socioeconomic class
Upper 05 (8.0) 04 (5.9) 0.172#
Upper middle 12 (19.3) 09 (13.4)
Lower middle 24 (38.7) 16 (23.8)
Upper lower 14 (22.5) 25 (37.3)
Lower 07 (11.2) 13 (19.4)
Co-morbidities
DM 15 (24.1) 18 (26.8) 0.603#
HTN 18 (29.0) 17 (25.3)
Hyperlipidaemia 9 (14.5) 10 (14.9)
DM + HTN 10 (16.1) 9 (13.4)
Hyperthyroidism 5 (8.0) 4 (5.9)
No comorbidities 5 (8.0) 9 (13.4)
Table 1.
Baseline demographics of study patients.

After using sertraline for 24 weeks, group B exhibited improved control over total cholesterol levels (from 161.1±17.5 mg/dL to 149.3±14.9 mg/dL), LDL (from 111.5±17.5 mg/dL to 110.4±16.4 mg/dL), and HDL (from 52.6±10.4 to 55.2±11.1) in comparison to group A. Blood pressure readings, HbA1c levels, showed stability in both the groups and no significant (p>0.05) alterations were noted in coagulation parameters. Table 2 shows post-stroke patients showed a more favourable response in TC, HDL, LDL and TG levels compared to post MI patients, but this difference was not statistically significant.

Clinical Parameters Treatment period Group A (N=62) Group B (N=67) p-value
TC Week 0 158.5±17.2 161.1±17.5 0.981#
Week 24 153.2±15.6 149.3±14.9
LDL Week 0 111.2±20.7 111.5±17.5 0.366#
Week 24 115.1±18.2 110.4±16.4
TG Week 0 142.4±14.1 144.5±13.2 0.261#
Week 24 134.2±13.6 132.4±10.2
Apo A Week 0 26.9±3.8 27.4±4.6 0.649#
Week 24 26.1±3.7 27.6±4.2
Apo B Week 0 105.3±12.3 106.7±11.8 0.827#
Week 24 105.1±17.2 106±11.6
SBP Week 0 128.8±10.5 127.8±10.6 0.575#
Week 24 127.9±10.9 126.7±9.9
DBP Week 0 78.7±4.1 79.4±3.9 0.490#
Week 24 78.2±3.1 78.9±3.5
PTT Week 0 28.9±1.9 29.0±1.6 0.790#
Week 24 29.5±1.8 29.9±2.0
PT Week 0 10.5±0.7 10.7±1.0 0.861#
Week 24 10.8±1.2 11.1±1.2
INR Week 0 0.9±0.12 0.9±0.17 0.474#
Week 24 0.8±0.23 0.9±0.1
Table 2.
Clinical parameter response to sertraline treatment between the groups.

Between group, revealed a significant improvement of HAM-D at week 24 (p=0.029). In the within-group comparison, improvement was observed from week 16 onwards, with group B demonstrating better clinical improvement in HAM-D scores compared to group A, indicating a stronger response in post-stroke patients, as depicted in Table 3.

Treatment period (Week) HAM-D score
Group A (n=62) Group B (n=67) p-value
0 l6.92±l.l l7.0l±l.3 0.428#
4 l6.84±l.5 l6.75±l.l 0.322#
8 l5.58±l.4 l6.l0±l.3 0.ll9#
12 l4.67±l.7 l4.69±l.l 0.327#
16 ll.69±l.0** l0.70±l.l** 0.l39#
20 8.50±l.l** 8.59±l.2** 0.2l7#
24 5.98±l.2*** 3.54±l.l*** 0.029*
Table 3.
Between and within group comparison of sertraline from baseline to week 24.

The medication adherence scores from the MARS Questionnaire for both groups during the treatment period was depicted in Table 4. Both groups exhibited no statistically significant differences at the end of the treatment period (week 24). On assessing health-related quality of life through RAND-36 scores, both groups showed improvement in overall well-being. Statistically significant improvements were observed (p=0.043) only in the physical well-being and role limitation due to emotional health (p=0.022) at the week 24.

Treatment period (Week) MARS Score p -value
Group A (N=62) Group B (N=67)
4 5.4±l.3 6.0±l.l 0.23l#
8 6.4±l.0 6.9±0.8 0.346#
l2 7.0±l.0 7.7±l.5 0.2l6#
l6 7.5±l.4 7.9±0.9 0.244#
20 7.9±l.5** 8.2±l.3** 0.334#
24 8.4±l.2** 8.9±0.7** 0.l46#
Table 4.
Between and within groups comparison of medication adherence using MARS Questionnaire.

DISCUSSION

This study divided patients into two groups: A, who had depression after a MI, and B, who had it after a stroke. Demographics showed normalized age, gender, education, employment, marital status, and family type across both groups. The individuals with cardiovascular and cerebrovascular diseases is rising rapidly, exposing middle-aged and older patients at risk (Yan & Hu, 2024). The patients in both the MI and stroke groups suffering from depression were between the ages of 51 and 60 years, concordant with our studies. In this study, we prescribed sertraline as the antidepressant of choice, focusing on its efficacy in treating depression among patients with MI and stroke.

Both groups had consistent HAM-D score reductions during treatment. This study found that sertraline significantly reduced depressive symptoms in stroke patients more than in MI patients, suggesting a better response to sertraline in stroke patients. This is possibly due to the complex relationship between depression and stroke-related neurological changes. Better clinical progress was seen in group B, which had higher response, remission, and relapse rates than group A. Differences were not statistically significant. In studies of coronary artery disease, including MI, sertraline reduced HAM-D scores and improved clinical outcomes (Blumenthalet al., 2012). Research by Bour et al., indicated that individuals suffering from depression after a stroke tend to exhibit unique symptoms compared to those with post-MI depression. Stroke patients more frequently show signs of loss of interest, psychomotor slowing, and vegetative symptoms, which are directly linked to the neurological impact of the stroke. In contrast, MI-related depression often arises from the sudden and life-threatening nature of the heart condition (Bouret al., 2009). Our findings suggest that the neurological factors involved in stroke may make these patients more responsive to sertraline treatment for depression, mirroring Bour et al., findings of the distinct nature of depression in stroke versus MI participants.

A meta-analysis found that many MI and stroke patients go untreated for depression, highlighting the need for better intervention strategies (Ladwiget al., 2018). Sertraline worked for both groups, but stroke patients responded better. This suggests cardiovascular patients need structured depression treatment. This study confirms the literature review that sertraline reduces depressive symptoms, especially in MI and stroke survivors. Sertraline’s safety, especially its low QT interval effect compared to other SSRIs, supports its use in this population (Zambranoet al., 2020). Contrary to our findings, a trial concluded that treatment with sertraline did not result in better improvements in symptoms of depression or cardiovascular conditions. Several other studies have also demonstrated enhanced depression outcomes in stroke patients treated with sertraline (Rasmussenet al., 2003; Stuckartet al., 2021).

Lipid profiles, blood pressure, HbA1c, and coagulation markers were examined in both groups to determine sertraline response. Group B’s lipid profiles improved, while Group A’s rose significantly from baseline. In both groups, the remaining clinical parameters changed minimal, reflecting only minor responses. A study of sertraline and fluoxetine in depression and diabetes patients found that sertraline reduced lipid profiles (Bayaniet al., 2024). But it raised triglycerides compared to before treatment (Kesimet al., 2011). Multiple studies have shown that sertraline worsens lipid profiles, which may increase lipid levels in certain patients (Weiet al., 2009; Beyazyüzet al., 2013). To avoid cardiovascular side effects, we should monitor patient’s lipid levels during sertraline treatment. Another study confirmed our findings that blood pressure and HbA1c levels were stable during treatment (Padmapriyaet al., 2020; Kesimet al., 2011). Sertraline may improve glycemic control, but its effects on BP are unclear (Bayaniet al., 2024). According to research, people who take sertraline have coagulation scores that are similar to those of healthy people. A few reports of bleeding issues have surfaced, but they don’t appear to be associated with changes in coagulation metrics. Therefore, it appears that sertraline has a minimal impact on coagulation (Geiseret al., 2011). Prior studies suggested that sertraline in depression patients with any coronary events could increase platelet inhibition in addition to concomitant medications (Serebruanyet al., 2003).

On comparing medication adherence, both groups demonstrated improved medication adherence. However, at the terminal phase of treatment, group B showed a numerical improvement in their MARS score compared to group A. Prior research has indicated that poor adherence to medication can worsen depression in cardiovascular conditions, highlighting the importance of consistent treatment (Ladwiget al., 2018). In contrast, a meta-analysis suggests that both post-MI and post-stroke conditions negatively impact medication adherence, increasing the risk of adverse health outcomes. The present study explains the greater reduction in depression symptoms in both groups, especially in group B, which suggests that improving adherence could be a key factor in enhancing treatment outcomes for depression in patients with cardiovascular conditions.

Assessing HRQoL helps understand the broader impact of treatments, guiding interventions that aim to improve daily functioning and long-term health outcomes for individuals with cardiovascular diseases. In this study, by the 24th week, both groups experienced improvements in HRQoL (Rahmanet al., 2024). However, group B demonstrated clinically better outcomes in all eight specific domains than group A. Research suggests that sertraline not only lowers depression levels but also positively impacts HRQoL over time (Lavuet al., 2022)

CONCLUSION

This study examines how sertraline affects depressive symptoms in MI and stroke patients, highlighting the link between cardiovascular health and mental health. Results showed significant improvements in depression, with post-stroke patients responding better to treatment than post-MI patients, as reflected in HAM-D scores. Improvements in clinical parameters, medication adherence, and quality of life were notable, especially in the stroke group. The findings emphasize the need for holistic strategies to manage both mental and physical health in cardiac patients with depression.

Cite this article:

Kumar V, Sriram NKA, Shanmugasundaram N, Selvan NP, Munirathinam D, etal. Effect of Sertraline in Newly Diagnosed Depression Patients with Post MI and Stroke: A Prospective Cohort Study. J Young Pharm. 2025;17(2):477-82.

ACKNOWLEDGEMENT

The authors are thankful for nurses from psychiatry department for their support in data collection process.

References

  1. Aw PY, Pang XZ, Wee CF, Tan NHW, Peck E-W, Teo YN, Teo YH, Syn NL, Chan MY, Tan BYQ, Chan KA, Yeo LLL, Chai P, Yeo T-C, Sia C-H, et al. (2023) Co-prevalence and incidence of myocardial infarction and/or stroke in patients with depression and/or anxiety: A systematic review and meta-analysis. Journal of Psychosomatic Research 165: Article 111141 https://doi.org/10.1016/j.jpsychores.2 022.111141 | Google Scholar
  2. Bayani MA, Roshan AT, Moudi S. (2024) Sertraline and fluoxetine in adult patients with comorbid depression and type II diabetes mellitus: A randomized controlled trial. Jundishapur Journal of Chronic Disease Care 13: Article e138454 https://doi.org/10.1016/j.jpsychores.2 022.111141 | Google Scholar
  3. Beyazyüz M, Albayrak Y, Eğilmez OB, Albayrak N, Beyazyüz E. (2013) Relationship between SSRIs and metabolic syndrome abnormalities in patients with generalized anxiety disorder: A prospective study. Psychiatry Investigation 10: 148-154 https://doi.org/10.4306/pi.2013.10.2.148 | Google Scholar
  4. Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Smith PJ, Hoffman BM, O’Hayer CVF, Mabe S, Johnson J, Doraiswamy PM, Jiang W, Schocken DD, Hinderliter AL, et al. (2012) Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: Results from the UPBEAT study. Journal of the American College of Cardiology 60: 1053-1063 https://doi.org/10.1016/j.jacc.2012.04.040 | Google Scholar
  5. Bour A, Rasquin S, Aben I, Strik J, Boreas A, Crijns H, Limburg M, Verhey F, et al. (2009) The symptomatology of post-stroke depression: Comparison of stroke and myocardial infarction patients. International Journal of Geriatric Psychiatry 24: 1134-1142 https://doi.org/10.1002/gps.2236 | Google Scholar
  6. Colotto M, Vinci F, Hong N, Raimo O, Castello A, Carnovale A, Paciaroni A, Coletta P, et al. (2012) Effect of treatment with selective serotonin reuptake inhibitors on lipid profile: State of the art. La Clinica Terapeutica 163: e41-e45 https://doi.org/10.1002/gps.2236 | Google Scholar
  7. Gandhi PA, Kishore J. (2020) Prevalence of depression and the associated factors among the software professionals in Delhi: A cross-sectional study. Indian Journal of Public Health 64: 413-416 https://doi.org/10.4103/ijph.IJPH_568_19 | Google Scholar
  8. Geiser F, Conrad R, Imbierowicz K, Meier C, Liedtke R, Klingmüller D, Oldenburg J, Harbrecht U, et al. (2011) Coagulation activation and fibrinolysis impairment are reduced in patients with anxiety and depression when medicated with serotonergic antidepressants. Psychiatry and Clinical Neurosciences 65: 518-525 https://doi.org/10.1111/j.1440-1819.2011.02241.x | Google Scholar
  9. Gurbel PA, Gattis WA, Fuzaylov SF, Gaulden L, Hasselblad V, Serebruany VL, O’Connor CM, et al. (2002) Evaluation of platelets in heart failure: Is platelet activity related to etiology, functional class, or clinical outcomes?. American Heart Journal 143: 1068-1075 https://doi.org/10.1067/mhj.2002.121261 | Google Scholar
  10. Kesim M, Tiryaki A, Kadioglu M, Muci E, Kalyoncu NI, Yaris E, et al. (2011) The effects of sertraline on blood lipids, glucose, insulin and HbA1c levels: A prospective clinical trial on depressive patients. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences 16: 1525-1531 https://doi.org/10.1067/mhj.2002.121261 | Google Scholar
  11. Ladwig S, Zhou Z, Xu Y, Wang X, Chow CK, Werheid K, Hackett ML, et al. (2018) Comparison of treatment rates of depression after stroke versus myocardial infarction: A systematic review and meta-analysis of observational data. Psychosomatic Medicine 80: 754-763 https://doi.org/10.1097/PSY.0000000000000632 | Google Scholar
  12. Lavu VK, Mohamed RA, Huang R, Potla S, Bhalla S, Al Qabandi Y, Nandula SA, Boddepalli CS, Gutlapalli SD, Mohammed L, et al. (2022) Evaluation and treatment of depression in stroke patients: A systematic review. Cureus 14: Article e28137 https://doi.org/10.7759/cureus.28137 | Google Scholar
  13. Li P, Wang H, Sun L. (Array) Comparison of therapeutic efficacy and safety of sertraline and paroxetine in the treatment of post-stroke depression. Chinese Pharmacology : 5098-5101 https://doi.org/10.7759/cureus.28137 | Google Scholar
  14. Li X, Zhou J, Wang M, Yang C, Sun G. (2023) Cardiovascular disease and depression: A narrative review. Frontiers in Cardiovascular Medicine 10: Article 1274595 https://doi.org/10.3389/fcvm.2023.1274595 | Google Scholar
  15. McRae AL, Brady KT. (2001) Review of sertraline and its clinical applications in psychiatric disorders. Expert Opinion on Pharmacotherapy 2: 883-892 https://doi.org/10.1517/14656566.2.5.883 | Google Scholar
  16. O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R, et al. (2010) Safety and efficacy of sertraline for depression in patients with heart failure: Results of the SADHART-CHF trial. Journal of the American College of Cardiology 56: 692-699 https://doi.org/10.1016/j.jacc.2010.03.068 | Google Scholar
  17. Padmapriya C, Pushkarapriya S, Shanmugapriya N, Sushmitha KP, Karthik S, Rajanandh MG, et al. (2020) Effect of sertraline in patients with newly diagnosed depression and type 2 diabetes mellitus or hypertension: An observational study from south India. Diabetes and Metabolic Syndrome 14: 1065-1068 https://doi.org/10.1016/j.dsx.2020.06.059 | Google Scholar
  18. Rahman AA, Platt RW, Beradid S, Boivin J-F, Rej S, Renoux C, et al. (2024) Concomitant use of selective serotonin reuptake inhibitors with oral anticoagulants and risk of major bleeding. JAMA Network Open 7: Article e243208 https://doi.org/10.1001/jamanetworkopen.2024.3208 | Google Scholar
  19. Rasmussen A, Lunde M, Poulsen DL, Sørensen K, Qvitzau S, Bech P, et al. (2003) A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 44: 216-221 https://doi.org/10.1176/appi.psy.44.3.216 | Google Scholar
  20. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, van Zyl LT, Finkel MS, Krishnan KRR, Gaffney M, Harrison W, Califf RM, O’Connor CM, et al. (2003) Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The sertraline antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 108: 939-944 https://doi.org/10.1161/01.CIR.0000085163.21752.0A | Google Scholar
  21. Serebruany VL, Gurbel PA, O’Connor CM. (2001) Platelet inhibition by sertraline and N-desmethylsertraline: A possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacological Research 43: 453-462 https://doi.org/10.1006/phrs.2001.0817 | Google Scholar
  22. Stuckart I, Siepmann T, Hartmann C, Pallesen L-P, Sedghi A, Barlinn J, Reichmann H, Puetz V, Barlinn K, et al. (2021) Sertraline for functional recovery after acute ischemic stroke: A prospective observational study. Frontiers in Neurology 12: Article 734170 https://doi.org/10.3389/fneur.2021.734170 | Google Scholar
  23. Wei F, Crain AL, Whitebird RR, Godlevsky OV, O’Connor PJ. (2009) Effects of paroxetine and sertraline on low-density lipoprotein cholesterol: An observational cohort study. CNS Drugs 23: 857-865 https://doi.org/10.2165/11310840-000000000-00000 | Google Scholar
  24. Yan N, Hu S. (2024) The safety and efficacy of escitalopram and sertraline in post-stroke depression: A randomized controlled trial. BMC Psychiatry 24: 365 https://doi.org/10.1186/s12888-024-05833-w | Google Scholar
  25. Zambrano J, Celano CM, Januzzi JL, Massey CN, Chung W-J, Millstein RA, Huffman JC, et al. (2020) Psychiatric and psychological interventions for depression in patients with heart disease: A scoping review. Journal of the American Heart Association 9: Article e018686 https://doi.org/10.1161/JAHA.120.018686 | Google Scholar